137 related articles for article (PubMed ID: 37438087)
1. Evaluating von Willebrand factor and ADAMTS13 levels in thalassemia major patients and assessing a possible association with Thrombospondin-1.
Al-Sabaan K; Al-Awadhi A
Int J Lab Hematol; 2023 Dec; 45(6):945-952. PubMed ID: 37438087
[TBL] [Abstract][Full Text] [Related]
2. Relationship of Thrombospondin 1 to von Willebrand Factor and ADAMTS-13 in Sickle Cell Disease Patients of Arab Ethnicity.
Al-Awadhi A; Adekile A; Marouf R
Acta Haematol; 2021; 144(2):182-189. PubMed ID: 32987383
[TBL] [Abstract][Full Text] [Related]
3. Determination of vWF, ADAMTS-13 and Thrombospondin-1 in Venous Thromboembolism and Relating Them to the Presence of Factor V Leiden Mutation.
Al-Awadhi A; Marouf R; Jadaon MM; Al-Awadhy MM
Clin Appl Thromb Hemost; 2024; 30():10760296231223195. PubMed ID: 38225166
[TBL] [Abstract][Full Text] [Related]
4. Role of thrombospondin-1 in control of von Willebrand factor multimer size in mice.
Pimanda JE; Ganderton T; Maekawa A; Yap CL; Lawler J; Kershaw G; Chesterman CN; Hogg PJ
J Biol Chem; 2004 May; 279(20):21439-48. PubMed ID: 14981081
[TBL] [Abstract][Full Text] [Related]
5. Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases.
Cibor D; Owczarek D; Butenas S; Salapa K; Mach T; Undas A
World J Gastroenterol; 2017 Jul; 23(26):4796-4805. PubMed ID: 28765701
[TBL] [Abstract][Full Text] [Related]
6. Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13.
Bonnefoy A; Daenens K; Feys HB; De Vos R; Vandervoort P; Vermylen J; Lawler J; Hoylaerts MF
Blood; 2006 Feb; 107(3):955-64. PubMed ID: 16204318
[TBL] [Abstract][Full Text] [Related]
7. Von Willebrand factor and ADAMTS13 activity as clinical severity markers in patients with COVID-19.
Marco A; Marco P
J Thromb Thrombolysis; 2021 Aug; 52(2):497-503. PubMed ID: 33866481
[TBL] [Abstract][Full Text] [Related]
8. ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: Evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy.
Henry BM; Benoit SW; de Oliveira MHS; Lippi G; Favaloro EJ; Benoit JL
Int J Lab Hematol; 2021 Jul; 43 Suppl 1(Suppl 1):129-136. PubMed ID: 33270980
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of von Willebrand factor and ADAMTS-13 antigen and activity levels in sickle cell disease patients in Kuwait.
Al-Awadhi A; Adekile A; Marouf R
J Thromb Thrombolysis; 2017 Jan; 43(1):117-123. PubMed ID: 27613177
[TBL] [Abstract][Full Text] [Related]
10. Von Willebrand Factor, ADAMTS13, and the Risk of Mortality: The Rotterdam Study.
Sonneveld MA; Franco OH; Ikram MA; Hofman A; Kavousi M; de Maat MP; Leebeek FW
Arterioscler Thromb Vasc Biol; 2016 Dec; 36(12):2446-2451. PubMed ID: 27737864
[TBL] [Abstract][Full Text] [Related]
11. Altered von Willebrand Factor and ADAMTS13 Levels in Children With Cirrhosis and Extrahepatic Portal Hypertension.
Islek A; Ilhan D; Ozturk N; Guven B; Sag E
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e951-e956. PubMed ID: 33369998
[TBL] [Abstract][Full Text] [Related]
12. Control of von Willebrand factor multimer size and implications for disease.
Pimanda J; Hogg P
Blood Rev; 2002 Sep; 16(3):185-92. PubMed ID: 12163004
[TBL] [Abstract][Full Text] [Related]
13. Relationship between ADAMTS13 activity, von Willebrand factor antigen levels and platelet function in the early and late phases after TIA or ischaemic stroke.
McCabe DJ; Murphy SJ; Starke R; Harrison P; Brown MM; Sidhu PS; Mackie IJ; Scully M; Machin SJ
J Neurol Sci; 2015 Jan; 348(1-2):35-40. PubMed ID: 25498844
[TBL] [Abstract][Full Text] [Related]
14. Changes in von Willebrand factor and ADAMTS-13 in patients following arthroplasty.
Liu L; Ling J; Ma Z; Yuan Q; Pan J; Yang H
Mol Med Rep; 2015 Apr; 11(4):3015-20. PubMed ID: 25482054
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the Diagnostic Value of Plasma Levels, Activities, and Their Ratios of von Willebrand Factor and ADAMTS13 in Patients with Cerebral Infarction.
Qu L; Jiang M; Qiu W; Lu S; Zhao Y; Xia L; Ruan C; Zhao Y
Clin Appl Thromb Hemost; 2016 Apr; 22(3):252-9. PubMed ID: 25916953
[TBL] [Abstract][Full Text] [Related]
16. Control of von Willebrand factor multimer size by thrombospondin-1.
Xie L; Chesterman CN; Hogg PJ
J Exp Med; 2001 Jun; 193(12):1341-9. PubMed ID: 11413189
[TBL] [Abstract][Full Text] [Related]
17. Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome.
Hulstein JJ; van Runnard Heimel PJ; Franx A; Lenting PJ; Bruinse HW; Silence K; de Groot PG; Fijnheer R
J Thromb Haemost; 2006 Dec; 4(12):2569-75. PubMed ID: 16968329
[TBL] [Abstract][Full Text] [Related]
18. Effect of hydroxyurea therapy on intravascular hemolysis and endothelial dysfunction markers in sickle cell anemia patients.
Chenou F; Hounkpe BW; Domingos IF; Tonassé WV; Batista THC; Santana RM; Arcanjo GDS; Alagbe AE; Araújo ADS; Lucena-Araújo AR; Bezerra MAC; Costa FF; Sonati MF; De Paula EV; Dos Santos MNN
Ann Hematol; 2021 Nov; 100(11):2669-2676. PubMed ID: 34453189
[TBL] [Abstract][Full Text] [Related]
19. Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction.
Matsukawa M; Kaikita K; Soejima K; Fuchigami S; Nakamura Y; Honda T; Tsujita K; Nagayoshi Y; Kojima S; Shimomura H; Sugiyama S; Fujimoto K; Yoshimura M; Nakagaki T; Ogawa H
Am J Cardiol; 2007 Sep; 100(5):758-63. PubMed ID: 17719316
[TBL] [Abstract][Full Text] [Related]
20. ADAMTS-13-VWF axis in sickle cell disease patients.
Ladeira VS; Barbosa AR; Oliveira MM; Ferreira LGR; de Oliveira Júnior WV; de Oliveira Renó C; Reis EA; Chaves DG; Dusse LMS; Dos Santos HL; de Barros Pinheiro M; Rios DRA
Ann Hematol; 2021 Feb; 100(2):375-382. PubMed ID: 33404693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
